Real-world Treatment Outcomes in People with Multiple Sclerosis Switched from Platform MS Treatments to Fumarates Versus Other Oral Disease-modifying Therapies (P8-1.010)
Assess the real-world effectiveness of fumarates (FUM) compared to sphingosine 1-phosphate receptor modulators (S1Ps) and cladribine (CLAD) in people with multiple sclerosis (MS) switching from platform MS disease-modifying therapies (DMTs) by evaluating annualized relapse rates (ARR), healthcare resource utilization (HCRU), and healthcare costs (HCC).
Authors
- Marijean Buhse
- Jose Avila-Ornelas (ORCID: https://orcid.org/0000-0002-4528-5359)
- Cortnee Roman (ORCID: https://orcid.org/0000-0001-7145-1640)
- Nicholas Belviso
- Sai L. Shankar (ORCID: https://orcid.org/0000-0003-3249-8360)
- James B. Lewin (ORCID: https://orcid.org/0000-0002-2352-9113)
- Yujie Wang (ORCID: https://orcid.org/0000-0002-0593-7439)
- Boyang Bian (ORCID: https://orcid.org/0000-0003-0153-4218)
- Khaled Awidat Abdalla
Institutions
- Biogen (United States) (US)
- University of Washington (US)
- Urology Associates (US)
- Rocky Mountain Multiple Sclerosis Clinic (US)
- Multiple Sclerosis Center of Atlanta (US)
- Winchester Medical Center (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208401
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00